Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02866136 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Conservative Treatments of Retinoblastoma

Study acronym: RETINO2011
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Jan 29, 2024, no change to tracked fieldsv10-v11
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Aug 2024 to Jan 2023
    • Study completion date: Feb 2027 to Sep 2035
    • Site details revised
    v9
  3. Primary completion date: Feb 28, 2019 to Aug 2024v8
  4. Primary completion date changed from estimate of Feb 2019 to Feb 28, 2019v7
  5. 2 versions Re-verified since Jul 21, 2017, no change to tracked fieldsv5-v6
Show 3 earlier versionsHide 3 earlier versions
  1. Site details revisedv4
  2. Re-verified, no change to tracked fieldsv3
  3. Eligibility criteria revised
    • Secondary endpoints: details revised at 2 of 6 entries
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Curie
43 trials monitored
See 1 trial at risk
Conservative treatments of retinoblastoma (RETINO 2011) 1. -Multicentric non randomised, phase II study for the patients treated by chemoreduction (VP16, carboplatin) followed by chemothermotherapy without laser treatment at day 8 2. -Multicentric non randomised, phase II study for the patients with bilateral very asymmetric dis-ease (Group D eye on one of the eye) or unilateral presentation groups B/C/D according to the age and vitreous seeding 3. \- Multicentric non randomised, phase II study for the patients treated by 6 cycles of three drugs regimen and local treatments for bilateral group D eyes or on the only eye.
Trial Details
NCT Number NCT02866136
Lead Sponsor Institut Curie
Collaborators: Fondation Rothschild Paris
Conditions
(from sponsor)		 Retinoblastoma, Children, Retinal Neoplasm
Related terms Retinal Neoplasms, Retinoblastoma
Enrollment 133 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov